ArticleFrontiers in cardiovascular medicine2025
A novel flow waveform partitioning method based on the HeartCon and its clinical application.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular assist device (LVAD) is a crucial therapy for end-stage heart failure. This research aimed to validate the correspondence between the HeartCon flow waveform and the cardiac cycle through animal experiments and propose a novel electrocardiogram (ECG)-guided partitioning method. The controlled variable method was employed to systematically investigate the effects of varying rotational speeds, heart rates, and blood pressures on the HeartCon flow waveform and the cardiac cycle. The results demonstrated that the proposed HeartCon partitioning method exhibited higher accuracy in assessing ejection fraction (EF), with absolute relative errors below 5% when compared to echocardiography, significantly outperforming the HeartWare Ventricular Assist Device (HVAD)-based partitioning method (absolute relative errors exceeding 40%). Furthermore, the study revealed that the diastolic phase proportion was consistently less than 58% of that in a normal heart under various physiological conditions and further shortened with increased heart rate, elevated rotational speed, and decreased blood pressure, suggesting a potential significant impact of aspiration force produced by the pump on the diastolic phase. Based on the experimental findings, a HeartCon cardiac Wiggers diagram was constructed, clearly illustrating the temporal relationship and key characteristics of pump flow, left ventricular pressure, and aortic pressure after LVAD implantation. This novel flow waveform partitioning method provides a theoretical foundation for the clinical application of the HeartCon pump and offers new avenues for clinicians to monitor and assess patients' physiological conditions through real-time flow waveforms. AI Assistance Declaration: During the preparation of this work, the authors used ChatGPT (OpenAI) to improve language and readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the publication's content.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.